Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Haitai Biological Pharmaceuticals, formally Zhuhai S.E.Z Haitai Biological Pharmaceuticals Co., Ltd., is a China-based healthcare company focused primarily on in vitro diagnostic reagents and ELISA-based test kits. The company was founded in 1991 in Zhuhai and has marketed diagnostic products including antibody detection kits for infectious diseases such as toxoplasmosis and rabies, with evidence of older TORCH-related assay development. Public business descriptions characterize Haitai as an early developer and manufacturer of IVD reagents and ELISA kits rather than a therapeutic drug developer. The company is active and appears to operate as a commercial diagnostics manufacturer. Corporate registry information indicates it is wholly owned by Wuhan Hiteck Biopharmaceutical and therefore functions as an acquired subsidiary rather than an independent public biotech.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Haitai Biological Pharmaceuticals.